Lixisenatide: 6 agencies, 2013–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where lixisenatide met resistance it was usually narrowed rather than refused: 4 of 5 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 5.8 years, from 24 Jun 2013 at ZIN (Netherlands) to 19 Mar 2019 at PHARMAC (New Zealand).
TLV (Sweden) changed its position: not recommended on 31 Jan 2014, restricted by 26 Feb 2015, after a resubmission.
No assessment is on file from HAS (France), PBAC (Australia) and CIPM (Spain), each among the eight highest-volume agencies here.
Nothing has been added since 2019; on this evidence the file is dormant.
ZIN (Netherlands) was first to assess lixisenatide, on 24 Jun 2013; PHARMAC (New Zealand) did not open a file until 19 Mar 2019 — a wide spread of 5.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 7 dated records fall in 2013 alone.
Restriction is doing real work here: 4 of 5 decisive outcomes narrowed lixisenatide to a subgroup rather than accepting or refusing it outright, at AWMSG (Wales), SMC (Scotland) and TLV (Sweden) among others.
TLV (Sweden) is the only agency to have returned to lixisenatide, recording 2 separate entries.
6 of the 18 agencies in this archive hold a record for lixisenatide.
The full ledger for lixisenatide reads 4 restricted, 1 other, 1 not recommended and 1 no benefit.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 19 Mar 2019 | Type 2 diabetes, with established cardiovascular disease | PTAC advice: No Formal Recommendation · decision reached | source |
| TLV (Sweden) | 26 Feb 2015 | Lyxumia ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| AWMSG (Wales) | 13 Dec 2013 | Treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering… | recommended with restrictions (full) | source |
| SMC (Scotland) | 9 Sep 2013 | Treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when thes… | accepted (restricted) | source |
| G-BA (Germany) | 5 Sep 2013 | Lyxumia — benefit assessment §35a | added benefit: not proven | source |
2 further decisions for lixisenatide, across 2 agencies, are not shown here. They link to 2 further source documents.
Related molecules
- liraglutide — divergent outcome (restricted vs not recommended) on a shared indication
- empagliflozin — same ATC class A10B — Diabetes
- dapagliflozin — same ATC class A10B — Diabetes
- semaglutide — same ATC class A10B — Diabetes
- metformin / sitagliptin — same ATC class A10B — Diabetes
- sitagliptin — same ATC class A10B — Diabetes
Coverage: 7 decisions for lixisenatide from 6 agencies, 2013 to 2019. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.